Skip to main content
Premium Trial:

Request an Annual Quote

Personalized Medicine in Actual Practice

An article in Forbes reports on new findings that show ImClone Systems' colon cancer drug Erbitux and a similar drug from Amgen, Vectibix, may not work in half of colon cancer patients. By using a genetic test, it can tell patients whether they have tumors with a mutation in kras that would make the drugs ineffective. "Largely what personalized medicine will be is telling people which drugs are out there that don't work so don't bother," says Leonard Saltz, Memorial-Sloan-Kettering colon cancer specialist. "Thou shalt not give Erbitux and Vectibix to patients with mutated kras; all it will do is give toxicity and run up the bill."

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.